Murphy Andrew C, Wechsler Marissa E, Peppas Nicholas A
Department of Chemical Engineering, The University of Texas at Austin, Austin, TX, 78712, USA.
Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, Austin TX, 78712, USA.
Curr Opin Biomed Eng. 2021 Sep;19. doi: 10.1016/j.cobme.2021.100318. Epub 2021 Jun 29.
Recent advancements in molecular recognition have provided additional diagnostic and treatment approaches for multiple diseases, including autoimmune disorders and cancers. Research investigating how the composition of biological fluids is altered during disease progression, including differences in the expression of the small molecules, proteins, RNAs, and other components present in patient tears, saliva, blood, urine, or other fluids, has provided a wealth of potential candidates for early disease screening; however, adoption of biomarker screening into clinical settings has been challenged by the need for more robust, low-cost, and high-throughput assays. This review examines current approaches in molecular recognition and biosensing for the quantification of biomarkers for disease screening and diagnostic outcomes.
分子识别领域的最新进展为多种疾病提供了额外的诊断和治疗方法，包括自身免疫性疾病和癌症。研究疾病进展过程中生物体液组成如何变化，包括患者眼泪、唾液、血液、尿液或其他体液中存在的小分子、蛋白质、RNA和其他成分表达的差异，为早期疾病筛查提供了大量潜在候选物；然而，将生物标志物筛查应用于临床环境受到了对更强大、低成本和高通量检测方法需求的挑战。本文综述了分子识别和生物传感领域用于疾病筛查和诊断结果生物标志物定量的当前方法。
